Intro

This chapter explores a pivotal $2 billion licensing agreement for the innovative cancer drug ISB-2001, marking a shift for Indian pharmaceutical companies towards biopharmaceuticals. It also analyzes the effects of the 'America First' policies on India's pharmaceutical industry and the need for local manufacturers to innovate and enhance their competitiveness.